One of the possible strategies that I've heard mention is that if Zenith were to be able to launch an IPO with the aim to fund research into their plethora of indications, that they would split the company into two (similar to what happened to Resverlogix). One arm would keep the revenue stream from apabetalone (current shareholders), the other would be the one that gets funded via the IPO.

That's just one scenario and given the "great" communication from headquarters that we're getting, it's just speculation at this time. I think we'll need to wait until the AGM in a month or so before we understand the strategy, if there even is one.

masila